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Abstract	
A recent disease prevalence study of the largest documented Down syndrome (DS) cohort in the
United States strongly suggested significant disparity in general infectious disease conditions among
individuals with DS versus those without DS. In this follow-up retrospective analysis, we explored
these differences in greater detail by calculating prevalence of 52 infectious diseases, across 28 years
of data among 6078 individuals with DS and 30,326 age- and sex-matched controls, abstracted from
electronic medical records within a large Midwestern health system.
We found that the DS cohort had higher prevalence of pneumonias (including aspiration, viral,
bacterial, pneumococcal, and unspecified/atypical); otitis externa; and the skin infections impetigo,
abscess, and cellulitis. To the contrary, the DS cohort had lower prevalence of many respiratory
infections other than pneumonia (including influenza, strep pharyngitis, upper respiratory infection,
sinusitis, tonsillitis, laryngitis, bronchitis, scarlet fever, and otitis media); sexually transmitted infections
(including bacterial vaginosis, chlamydia, genital herpes, HIV/AIDS, human papillomavirus, pelvic
inflammatory disease, and trichomoniasis); mononucleosis; shingles; unspecified hepatitis; intestinal
infections; and enteritis. These findings highlight that individuals with DS could be more or less
prone to different infectious diseases than their non-DS matched counterparts. Additional research to
understand why these differences exist and how they might affect the clinical approach to patients with
DS is warranted. (J Patient Cent Res Rev. 2022;9:64-69.)
Keywords

Down syndrome; prevalence; infectious disease; pneumonia; skin; influenza; sinusitis; bronchitis; STI

A

recent study of the largest documented cohort
of individuals with Down syndrome (DS) in the
United States described the prevalence of a broad
range of disease conditions.1 Findings strongly suggested
a particularly significant disparity in infectious disease
among individuals with DS when compared with ageand sex-matched individuals without DS.1
Individuals with DS may be particularly vulnerable to
infectious diseases due to factors that increase risk of
contracting infections, including an impaired immune
system, an accelerated aging process, and structural
abnormalities.2-6 Reduced T- and B-cell counts, a smaller
thymus size, subpar antibody response to vaccinations,
and decreased chemotaxis seen in individuals with DS
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contribute to their decreased immune response.2 It is well
known that pneumonias are widespread in adults with DS,
with increased hospitalization and mortality; however,
other infectious disease prevalences are less known.2-9
While it has been reported that individuals with DS have
lower prevalence of sexually transmitted infections (STIs)
than the general population;10 very little research has
gone into characterizing STIs in children and adults with
DS. In the general population, chlamydia, gonorrhea, and
syphilis have been on the rise for the past several years,11
further warranting an examination into STI rates in the
DS population to better guide sex education guidelines.
Given that prevalence of DS itself is increasing4 and that
the lifespan for individuals with DS continues to grow,3-7
diving further into the specific infections unique to this
population is critical to best tailor care.
Herein, this study utilized clinical data representing
the largest reported sample of individuals with DS in
the United States, treated across a single Midwestbased integrated health system that includes the largest
Brief Report

center of DS care for adolescents and adults, to explore
infection prevalences among those diagnosed with DS.
Learning critical information on the most common
infectious diseases seen in these individuals might serve
to better guide practitioners in their attempts to provide
patient-centered care.

METHODS

This retrospective, descriptive cohort study, which
utilized 28 years of available encounter data (May
1991–September 2019) abstracted from electronic
medical records collected from all sites within one of
the largest nonprofit health systems in the United States,
was determined to be non-human subjects research by
the institutional review board. Full details on the data
collection methods for this overall study population can
be found in the previously published parent report.1
Participants

A total of 6078 cases, deemed eligible for inclusion
based on having at least 1 encounter with an International
Classification of Diseases (ICD) code of DS, were
identified. Comparable control patients included up to 5
individuals without a diagnosis of DS who were matched
to each case on year of birth (±1 year) and sex by a
data analyst. This approach resulted in 30,326 eligible
controls. Of the 6078 cases, 64 were assigned only 4 (as
opposed to 5) matched controls.
Procedures

This study design preidentified specific infectious
disease conditions of interest to assess prevalence among
individuals with DS versus those without. Conditions
were chosen based on existing literature and the clinical
expertise of one of the authors (B.C.). This study used
the U.S. Clinical Modification (CM) codes for medical
diagnoses based on the statistical classification of disease
denoted in the World Health Organization’s publication
of the ICD.12 Specifically, 10th Revision (ICD-10-CM)
and 9th Revision (ICD-9-CM) codes were used. A few
conditions of interest did not align clearly with ICD9-CM codes and, instead, AHRQ CCS categories were
used. See Table 1 for a complete list of infectious disease
conditions of interest and associated ICD codes.
Statistical Methods

Demographics are reported as means with standard
deviations and medians with ranges for age and total
encounters per sample. Sex, race, ethnicity, and
insurance type are reported as counts with percentages.
Clinical conditions are reported as counts with
percentages and odds ratios (OR) representing the
odds of cases having an infectious disease relative to
controls. Corresponding Pearson’s chi-squared P-values
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represent statistically significant differences (at an alpha
of <0.05) in prevalence of diagnoses between cases and
controls. Fisher’s exact P-value was interpreted when
any sample count was less than 5.

RESULTS

The DS case population was predominantly White
(77.35%) and of non-Hispanic/Latino ethnicity (73.51%).
Cases had a median of 6 total encounters (ie, clinical
visits in the health system) in the dataset. The control
cohort was also predominantly White (61.97%) and of
non-Hispanic/Latino ethnicity (81.72%), with a median
of 7 total encounters in the dataset. Both groups were
approximately 52% male and had a median age of 25
years. For complete demographics of the DS and matched
control cohorts, the reader is referred to the relevant table
published within this project’s parent article.1
The following paragraphs highlight statistically
significant ORs (95% CI) and P-values that were derived
from comparing prevalence of clinical infectious disease
conditions of interest among individuals with DS (ie,
cases) to matched controls. Table 2 shows both significant
and nonsignificant analysis results.
Relative to controls, individuals with DS had significantly
greater odds of experiencing any pneumonia (OR: 4.13
[3.74, 4.56]; P<0.0001) and, specifically, aspiration (OR:
10.50 [7.73, 14.28]; P<0.0001), viral (OR: 13.14 [8.12,
21.26]; P<0.0001), bacterial (OR: 4.72 [3.52, 6.33];
P<0.0001), pneumococcal (OR: 6.87 [2.76, 17.09];
P<0.0001), and unspecified or atypical pneumonia (OR:
3.69 [3.31, 4.11]; P<0.0001). The DS cohort also had more
frequent otitis externa (OR: 1.68 [1.42, 1.98]; P<0.0001)
and one or more of the skin infections impetigo, abscess,
and cellulitis (OR: 1.74 [1.62, 1.88]; P<0.0001).
Conversely, relative to controls, individuals with
DS had lesser odds of experiencing the following
infectious diseases: influenza (OR: 0.62 [0.52, 0.75];
P<0.0001); streptococcal pharyngitis (OR: 0.27 [0.22,
0.33]; P<0.0001); upper respiratory infection (OR: 0.37
[0.34,0.40]; P<0.0001); sinusitis (OR: 0.38 [0.34, 0.42];
P<0.0001); tonsillitis (OR: 0.58 [0.51, 0.65]; P<0.0001);
laryngitis (OR: 0.81 [0.68, 0.97]; P=0.0218); bronchitis
(OR: 0.48 [0.42, 0.56]; P<0.0001); scarlet fever (OR:
0.36 [0.17, 0.78]; P=0.0070); otitis media (OR: 0.77
[0.70, 0.85]; P<0.0001); and the STIs bacterial vaginosis
(OR: 0.14 [0.10, 0.19]; P<0.0001), chlamydia (OR: 0.07
[0.01, 0.53]; P<0.0001), genital herpes (OR: 0.08 [0.03,
0.21]; P<0.0001), HIV/AIDS (OR: 0.31 [0.13, 0.77];
P=0.0074), human papillomavirus (OR: 0.35 [0.21,
0.59]; P<0.0001), pelvic inflammatory disease (OR: 0.29
[0.12, 0.72]; P=0.0045), and trichomoniasis (OR: 0.08
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Table 1. Infectious Disease Conditions of Interest and Associated Codes
Infection type

Respiratory
Coronaviruses (excludes COVID-19)
Diphtheria
Influenza
Haemophilus influenzae type B
Measles
Mumps
Rubella (German measles)
Whooping cough (pertussis)
Strep pharyngitis
Upper respiratory infection
Sinusitis
Tonsillitis
Laryngitis
Bronchitis
Scarlet fever
Otitis media
Pneumonia
Aspiration
Viral
Bacterial
H. influenzae-caused
Pneumococcal
Unspecified/Atypical
Sexually transmitted
Bacterial vaginosis
Chlamydia
Gonorrhea
Genital herpes
HIV/AIDS
Human papillomavirus
Pelvic inflammatory disease
Syphilis
Trichomoniasis
Urinary tract infection
Other infection
Otitis externa
Infectious mononucleosis
Zika
Shingles (Herpes zoster)
Tetanus (lockjaw)
Norovirus
Polio
Meningococcal disease
Hepatitis
Hepatitis A
Hepatitis B, acute
Other acute hepatitis
Chronic viral hepatitis
Unspecified hepatitis
Ebola
Skin infections (impetigo, abscess, cellulitis)
Intestinal infections
Enteritis
Lyme disease

ICD-10-CM code

ICD-9-CM or AHRQ24 code

B342
A36
J09–J11
A492
B05
B26
B06
A37
J020
J069
J01, J32
J03, J35
J04–J05, J37
J20
A38
H669
J12–J15, J18, J690
J12–J15, J18, J690
J12
J15
J14
J13
J18, J690

07989
032
AHRQ 123
0415
055
0727–0729
056
033
0340
4659
461, 473
463, 47400–47402
4640, 4760
AHRQ 125, 490, 49122
0341
3829
AHRQ 122
AHRQ 122
4809
4829
4822
481
486, 5070

N76
A55–A56
A54
A60
B20
R8781–R8782
A1817, A5424, A5611, N73, N74
A50–A53
A59
N398

61610
07988, 07998
098
0541
AHRQ 5
0794
614
090–097
131
5990

H609
B27
A925
B02
A35
A0811
A80
A390, A3950–A3953, A3981–A3984, A3989, A399
B15–B19
B15
B16
B17
B18
B19
A984
L00–L039, L08
A08–A09
K529
A6920

38010
075
0663
053
037
00863
045
036
AHRQ 6
–
–
–
–
–
0658, 07889
AHRQ 197, 684
AHRQ 135
5589
08881

AHRQ, Agency for Healthcare for Research and Quality; CM, Clinical Modifications; ICD, International Classification of Diseases.
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Table 2. Prevalence of Infectious Conditions of Interest Among Cases vs Controls
DS sample
(n=6078)

Controls
(n=30,326)

OR (95% CI)

Pa

Respiratory
Coronaviruses (excludes COVID-19)
Diphtheria
Influenza
Haemophilus influenzae type B
Measles
Mumps
Rubella (German measles)
Whooping cough (pertussis)
Strep pharyngitis
Upper respiratory infection
Sinusitis
Tonsillitis
Laryngitis
Bronchitis
Scarlet fever
Otitis media
Pneumonia
Aspiration
Viral
Bacterial
H. influenzae-caused
Pneumococcal
Unspecified/Atypical

0
0
128
0
3
0
2
1
116
756
387
314
148
236
7
564
746
126
60
87
11
2
596

1
0
1010
0
3
6
2
19
2027
8384
4616
2624
902
2334
96
3541
993
61
23
93
8
0
868

–
–
0.62 (0.52, 0.75)
–
4.99 (1.01, 24.74)
–
4.99 (0.70, 35.44)
0.26 (0.04, 1.96)
0.27 (0.22, 0.33)
0.37 (0.34, 0.40)
0.38 (0.34, 0.42)
0.58 (0.51, 0.65)
0.81 (0.68, 0.97)
0.48 (0.42, 0.56)
0.36 (0.17, 0.78)
0.77 (0.70, 0.85)
4.13 (3.74, 4.56)
10.50 (7.73, 14.28)
13.14 (8.12, 21.26)
4.72 (3.52, 6.33)
6.87 (2.76, 17.09)
–
3.69 (3.31, 4.11)

1.0000b
–
<0.0001
–
0.0626b
0.5981b
0.1323b
0.2321b
<0.0001
<0.0001
<0.0001
<0.0001
0.0218
<0.0001
0.0070
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.0279b
<0.0001

Sexually transmitted
Bacterial vaginosis
Chlamydia
Gonorrhea
Genital herpes
HIV/AIDS
Human papillomavirus
Pelvic inflammatory disease
Syphilis
Trichomoniasis
Urinary tract infection

32
1
7
4
5
16
5
5
1
2

1128
68
55
255
80
224
85
45
62
25

0.14 (0.10, 0.19)
0.07 (0.01, 0.53)
0.63 (0.29, 1.39)
0.08 (0.03, 0.21)
0.31 (0.13, 0.77)
0.35 (0.21, 0.59)
0.29 (0.12, 0.72)
0.55 (0.22, 1.40)
0.08 (0.01, 0.58)
0.40 (0.09, 1.68)

<0.0001
<0.0001b
0.2533
<0.0001b
0.0074
<0.0001
0.0045
0.2039
0.0003b
0.2992b

193
8
0
17
0
2
0
0
42
4
4
1
26
6
0
1035
65
131
4

582
124
0
322
1
3
3
0
189
12
19
6
120
75
0
3201
639
1277
16

1.68 (1.42, 1.98)
0.32 (0.16, 0.66)
–
0.26 (0.16, 0.43)
–
3.33 (0.56, 19.92)
–
–
1.11 (0.79, 1.55)
1.66 (0.54, 5.16)
1.05 (0.36, 3.09)
0.83 (0.10, 6.91)
1.08 (0.71, 1.65)
0.40 (0.17, 0.92)
–
1.74 (1.62, 1.88)
0.50 (0.39, 0.65)
0.50 (0.42, 0.60)
1.25 (0.42, 3.73)

<0.0001
0.0010
–
<0.0001
1.0000b
0.1968b
1.0000b
–
0.5435
0.3257b
1.0000b
1.0000b
0.7180
0.0248
–
<0.0001
<0.0001
<0.0001
0.7622b

Infection type

Other infection
Otitis externa
Infectious mononucleosis
Zika
Shingles (Herpes zoster)
Tetanus (lockjaw)
Norovirus
Polio
Meningococcal disease
Hepatitis
Hepatitis A
Hepatitis B, acute
Other acute hepatitis
Chronic viral hepatitis
Unspecified hepatitis
Ebola
Skin infections (impetigo, abscess, cellulitis)
Intestinal infections
Enteritis
Lyme disease
a

Statistical significance was reached at an alpha of <0.05.

b

Fisher's exact test P-value was interpreted due to low sample count.

DS, Down syndrome; OR, odds ratio.
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[0.01, 0.58]; P=0.0003). The DS cohort also had less
frequently diagnosed infectious mononucleosis (OR:
0.32 [0.16, 0.66]; P=0.0010); shingles (OR: 0.26 [0.16,
0.43]; P=0.0248); unspecified hepatitis (OR: 0.40 [0.17,
0.92]; P=0.0248); intestinal infection (OR: 0.50 [0.39,
0.65]; P<0.0001); and enteritis (OR: 0.50 [0.42, 0.60];
P<0.0001).

DISCUSSION

Generally, our findings support similar data of
this range and magnitude available from previous
research.13 Individuals with DS had lower prevalence
of most respiratory infections but, consistent with
other findings, higher prevalence of the more severe
infections of pneumonia.14-16 Immune defects and
airway anatomical abnormalities, and an inability to
handle secretions, have been noted to explain increased
infections among individuals with DS.14 Furthermore,
encounter-level provider documentation habits could
explain discrepancies; specifically, if a condition that
may be assessed as more severe (eg, pneumonia) or as
a complication of an initial infection is diagnosed, then
less severe or initial conditions (eg, influenza, sinusitis,
laryngitis) may be left undocumented.
Specific to STIs, individuals with DS in our study had
lower prevalence, most to a statistically significant degree,
which could be due to less sexual activity contributed
to by noted delays in sexual maturity.17 Overall, there
are limited data on sexual activity of individuals with
intellectual disabilities, including individuals with DS,
as data are often reported by caregivers rather than the
individual with DS and providers are less likely to test
this population based on perceived risk, potentially
further affecting findings.18-20
Recent research among ambulatory and hospitalized
adults with DS concluded that, despite an overall
low rate of infections among ambulatory patients,
hospitalized adults were mostly admitted for infections
and that infections were associated with neurological
degeneration and increased mortality.21 Furthermore,
specific to the COVID-19 virus, the small group
of individuals with DS hospitalized for COVID-19
displayed more severe cases than controls, particularly
an increased incidence of sepsis and mechanical
ventilation.22 Additional research to understand unique
prevalence of varying infections and subsequent unique
effects on individuals with DS is necessary.
Strengths/Limitations

Our DS cohort is one of the largest to date, making it
suitable for the analysis of relatively rare morbidities
of interest. Incorporating the earliest available patient
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data, which represented a 28-year span, allowed for a
comprehensive look at prevalence. Our analysis also
included a large group of controls matched by age and
sex, a sample that can be viewed as representative of
a U.S. patient population without DS. Differences in
race, ethnicity, and insurance should be noted, as these
differences may have been contributors to or effects of
findings, or both.
While findings represent data from only a single health
system, such a large system may provide the most
accurate and available review of prevalence nationally,
given the United States’ fragmented storage of patient
data. Furthermore, much of the dataset was drawn from
a specialized care center specifically serving adults with
DS, which may improve diagnostic accuracy of ICD
coding and subsequent prevalence findings. A minority
of data came from other nonspecialized system sites less
familiar with serving adults with DS, potentially affecting
diagnostic consistency. It should be noted that diagnostic
accuracy in general can be difficult with individuals with
DS for a variety of reasons.23 While the conditions of
interest in this study incorporated an established coding
framework of ICD codes24 and were carefully chosen
and reviewed by a physician who specializes in treating
DS, it must be acknowledged that the utilized codes may
not be ones most commonly used to diagnose conditions
among patients with DS, introducing the potential for
underrepresentation of conditions. It is also possible
that these codes could over- or underrepresent diagnoses
among individuals with DS relative to those without DS.
This study looked at all individuals with DS, including
youth and adults, and reported prevalence of conditions
among them relative to controls. Future longitudinal
analyses are necessary to look at conditions across time,
to report on youth and adults separately, and to track
the course of conditions seen at different life stages of
individuals with DS, particularly as the average lifespan
continues to increase.

CONCLUSIONS

This follow-up report to a previously published general
prevalence study among individuals with Down
syndrome1 drills down specifically into infectious
diseases. Among one of the largest known DS cohorts
with matching controls in the United States, diagnosis
of numerous infectious disease conditions significantly
differed between those with and without DS. In
particular, pneumonias were more prevalent and sexually
transmitted infections less prevalent in individuals with
DS. Findings can be used to better inform and guide both
primary and specialized practitioners in the screening
and treatment of this unique patient population.

Brief Report

Patient-Friendly Recap
• Authors used longitudinal data from patient records
at a single health system to compare rates of
relatively common infectious diseases in those with
Down syndrome (DS) versus a control cohort of
similar patients without DS, documenting diagnosis
of infections as more or less prevalent.
• Individuals with DS were significantly more likely
to have pneumonias and skin infections and less
likely to have most other respiratory (eg, influenza,
bronchitis, sinusitis) or sexually transmitted infections
than their age- and sex-matched counterparts.
•D
 iffering infectious disease prevalences can be used
to guide primary and specialized practitioners in the
screening, diagnosis, and care of people with DS.
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